Use of selpercatinib in a patient with <i>RET</i>-mutated non-small cell lung cancer: case report
Background. The use of the modern targeted drugs in patients with non-small-cell lung cancer (NSCLC) with certain somatic alterations (genetic alterations in EGFR, ALK, ROS1, BRAF, RET genes, etc.) provides a significant increase in overall and disease-free survival with an acceptable toxicity profi...
Saved in:
| Main Authors: | A. M. Kazakov, K. K. Laktionov, V. O. Vorobyeva, K. A. Sarantseva |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2024-05-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/3049 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Case report: Selpercatinib in the treatment of RET fusion-positive advanced lung adenocarcinoma: a challenging clinical case
by: Raffaella Pagliaro, et al.
Published: (2025-01-01) -
Selpercatinib in the treatment of medullary and radioiodine-refractory differentiated thyroid cancer with RET mutation (literature review)
by: E. V. Borodavina, et al.
Published: (2025-03-01) -
Management and Long-Term Monitoring of a Young Patient with Pheochromocytoma and RET Mutation: A Case Report
by: Zhang Q, et al.
Published: (2025-03-01) -
Activation of the AKT-mTOR pathway confers selpercatinib resistance in thyroid cancer cells harboring the CCDC6-RET fusion gene
by: Masatsugu Amitani, et al.
Published: (2025-09-01) -
Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer
by: Lei Wang, et al.
Published: (2025-01-01)